Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody-Reference-Cited by-同舟云学术

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

Published:2021-02-19 Issue:6531 Volume:371 Page:823-829
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Rappazzo C. Garrett¹^ORCID,Tse Longping V.²^ORCID,Kaku Chengzi I.¹^ORCID,Wrapp Daniel³^ORCID,Sakharkar Mrunal¹,Huang Deli⁴^ORCID,Deveau Laura M.¹^ORCID,Yockachonis Thomas J.⁵^ORCID,Herbert Andrew S.⁶⁷^ORCID,Battles Michael B.¹^ORCID,O’Brien Cecilia M.⁶⁷^ORCID,Brown Michael E.¹^ORCID,Geoghegan James C.¹,Belk Jonathan¹,Peng Linghang⁴,Yang Linlin⁴^ORCID,Hou Yixuan²^ORCID,Scobey Trevor D.²,Burton Dennis R.⁴⁸⁹¹⁰^ORCID,Nemazee David⁴^ORCID,Dye John M.⁶^ORCID,Voss James E.⁴^ORCID,Gunn Bronwyn M.⁵^ORCID,McLellan Jason S.³^ORCID,Baric Ralph S.²¹¹^ORCID,Gralinski Lisa E.²^ORCID,Walker Laura M.¹¹²^ORCID

Affiliation:

1. Adimab, LLC, Lebanon, NH 03766, USA.

2. Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

3. Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

4. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

5. Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA.

6. U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.

7. The Geneva Foundation, Tacoma, WA 98402, USA.

8. IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

9. Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

10. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA.

11. Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

12. Adagio Therapeutics, Inc., Waltham, MA 02451, USA.

Abstract

Targeting sarbecoviruses As we continue to battle the COVID-19 pandemic, we must confront the possibility of new pathogenic coronaviruses emerging in humans in the future. With this in mind, Rappazzo et al. isolated antibodies from a survivor of the 2003 severe acute respiratory syndrome coronavirus (SARS-CoV), used yeast display libraries to introduce diversity into these antibodies, and then screened for binding to SARS-CoV-2. One of the affinity-matured progeny strongly neutralized SARS-CoV-2, SARS-CoV, and two SARS-related viruses from bats. In addition, this antibody bound to the receptor-binding domains from a panel of sarbecoviruses, suggesting broader activity, and provided protection against SARS-CoV and SARS-CoV-2 in mouse models. Science , this issue p. 823

Funder

National Institutes of Health

Bill and Melinda Gates Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference50 articles.

1. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

2. Origin and evolution of pathogenic coronaviruses

3. Broad neutralization of SARS-related viruses by human monoclonal antibodies

4. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

5. A human monoclonal antibody blocking SARS-CoV-2 infection

Cited by 274 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain;Structure;2024-02

2. Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation;ACS Infectious Diseases;2024-01-28

3. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination;2024-01-23

4. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques;Nature Communications;2024-01-03

5. Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants;Journal of Virology;2023-12-21